ESALY - Eisai Co., Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3016
http://www.eisai.co.jp

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees10,683

Key Executives

NameTitlePayExercisedYear Born
Mr. Haruo NaitoCEO, Representative Corp. Officer & DirectorN/AN/A1947
Mr. Gary HendlerSr. VP & Pres of EMEA RegionN/AN/A1966
Dr. Lynn D. KramerVP and Chief Clinical Officer & Chief Medical Officer - Neurology Bus. GroupN/AN/A1950
Ms. Shaji ProcidaVP and Pres & COO of Eisai Inc.N/AN/A1971
Mr. Nadeem SarwarPresN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia. It also offers Aricept for the treatment of Alzheimer's disease/dementia with Lewy bodies worldwide; and BELVIQ, an antiobesity agent in the United States. In addition, it develops Halaven, an anticancer agent in the oncology area for use in the treatment of breast cancer in approximately 65 countries and also for use in the treatment of malignant soft tissue sarcoma in 50 countries; and Lenvima, an anticancer agent for use in the treatment of thyroid cancer in Japan, the United States, Europe, and Asia. Further, the company has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma in the United States and Europe. It has a strategic collaboration with Merck & Co., Inc. for Lenvima in the oncology and dementia fields; and a collaboration agreement with Ono Pharmaceutical Co., Ltd. to develop the combination therapy of Lenvima and Opdivo for the treatment of hepatocellular carcinoma. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

Corporate Governance

Eisai Co., Ltd.’s ISS Governance QualityScore as of June 25, 2019 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 10; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.